Market Spotlight: Osteoarthritis and Osteoarthritis Pain
|出版日期||內容資訊||英文 49 Pages
|焦點市場分析:骨關節炎 Market Spotlight: Osteoarthritis and Osteoarthritis Pain|
|出版日期: 2020年08月21日||內容資訊: 英文 49 Pages||
根據Datamonitor Healthcare的數據，全球30歲以上的成人中，骨關節炎(膝或髖關節)的患病人數2017年推算為3億890萬人，預計2026年之前將增加到3億5,840萬人。全球骨關節炎的盛行率推算為8.2％。 骨關節炎領域批准的藥物集中於多種靶標。這些治療方法大多數是通過口服途徑進行的，其餘的則是局部，關節內和經皮的治療。
This Market Spotlight report covers the Osteoarthritis and Osteoarthritis Pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Datamonitor Healthcare estimates that in 2019, there were 320.7 million prevalent cases of osteoarthritis (knee or hip) in adults aged 30 years and older worldwide, and forecasts that number to increase to 367.7 million prevalent cases by 2028.
The global prevalence of osteoarthritis is estimated to be 8.2%. The approved drugs in the osteoarthritis space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being topical, intraarticular, and transdermal formulations.
The majority of industry-sponsored drugs in active clinical development for osteoarthritis are in Phase II, with only one drug in the NDA/BLA phase.
Therapies in development for osteoarthritis focus on a wide variety of targets. The largest proportion of pipeline drugs are administered via the intraarticular route.
High-impact upcoming events for drugs in the osteoarthritis space comprise topline Phase II and Phase III trial results, an expected PDUFA date for a BLA, an anticipated FDA advisory panel meeting, an expected decentralized approval in the EU, and an expected CHMP opinion.
The overall likelihood of approval of a Phase I osteoarthritis and osteoarthritis pain asset is 12.3%, and the average probability a drug advances from Phase III is 54.5%. Drugs, on average, take 12.7 years from Phase I to approval in the osteoarthritis and osteoarthritis pain space, as well as in the overall rheumatology (non autoimmune) space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for osteoarthritis have been in the early and mid-phases of development, with 58% of trials in Phase I-II, and 42% in Phase III-IV.
The US has a substantial lead in the number of osteoarthritis clinical trials globally. The UK leads the major European markets, while South Korea has the top spot in Asia.
Clinical trial activity in the osteoarthritis space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for osteoarthritis, with 124 trials.
Pfizer leads industry sponsors with the highest overall number of clinical trials for osteoarthritis